TELAVIC® 250 mg Tablets, Antiviral
Application for Additional Indication for Chronic Hepatitis C Genotype 2

Osaka, Japan, January 16, 2014---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) submitted recently an application for partial changes relating to an additional indication of chronic hepatitis C genotype 2 for TELAVIC® 250mg Tablets (generic name: telaprevir) (hereinafter, Telavic).

An estimated 1.5 to 2 million people are known to be infected with hepatitis C virus (HCV) in Japan, and approximately, 70% of these carriers have genotype 1, and approximately 30% of them have genotype 2.

Telavic, an orally available treatment of chronic hepatitis C, inhibits the NS3-4A serine protease thereby suppresses the replication of HCV. It has been treated for improving viremia in patients with HCV genotype 1 in triple combination therapy (telaprevir+ pegylated interferon α-2b (recombinant) + ribavirin) since November 2011.

For naïve patients with HCV genotype 2, combination therapy (pegylated interferon α -2b (recombinant) + ribavirin) is established as the standard of care (SOC), however, there is no standard therapy for patients with prior treatment failures.

Results of clinical studies for patients in Japan with HCV genotype 2 who were non-responders and relapers to the conventional treatment showed that Telavic-based triple combination therapy was effective; and an application was submitted for an additional indication of HCV genotype 2.

By providing appropriate usage information, Mitsubishi Tanabe Pharma will contribute to treatment of many patients with HCV.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211